Press Releases Stay on top of the latest news from Poseida Therapeutics. Learn about our leading-edge cell and gene therapy programs, from new discoveries to clinical trials, and get the most recent investor news. IR Sub Menu Investors & Media Corporate Profile Press Releases Events & Presentations Publications Year None20222021202020192018201720162015 Poseida Therapeutics Reports Operational Update and Financial Results for Third Quarter 2020 11/12/2020 Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate Cancer 11/02/2020 Poseida Therapeutics and TScan Therapeutics Announce Research Collaboration and License Agreement to Explore Developing Allogeneic T Cell Receptor Therapies for the Treatment of COVID-19 10/21/2020 Poseida Therapeutics Added to Membership of US Small-Cap Russell 2000® Index 09/18/2020 Poseida Therapeutics to Present CAR-T Manufacturing Process Optimization Data at CAR-TCR Digital Week 2020 09/16/2020 Poseida Therapeutics Reports Operational Update and Financial Results for Second Quarter and First Half of 2020 08/20/2020 Poseida Therapeutics Appoints Harry J. Leonhardt, Esq. as General Counsel 07/16/2020 Poseida Therapeutics Announces Pricing of Initial Public Offering 07/09/2020 Poseida Therapeutics Raises $110 Million in Series D Financing 06/25/2020 Poseida Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate Cancer 05/20/2020 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Next page next › Last page last » Displaying 31 - 40 of 84
Year None20222021202020192018201720162015 Poseida Therapeutics Reports Operational Update and Financial Results for Third Quarter 2020 11/12/2020 Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate Cancer 11/02/2020 Poseida Therapeutics and TScan Therapeutics Announce Research Collaboration and License Agreement to Explore Developing Allogeneic T Cell Receptor Therapies for the Treatment of COVID-19 10/21/2020 Poseida Therapeutics Added to Membership of US Small-Cap Russell 2000® Index 09/18/2020 Poseida Therapeutics to Present CAR-T Manufacturing Process Optimization Data at CAR-TCR Digital Week 2020 09/16/2020 Poseida Therapeutics Reports Operational Update and Financial Results for Second Quarter and First Half of 2020 08/20/2020 Poseida Therapeutics Appoints Harry J. Leonhardt, Esq. as General Counsel 07/16/2020 Poseida Therapeutics Announces Pricing of Initial Public Offering 07/09/2020 Poseida Therapeutics Raises $110 Million in Series D Financing 06/25/2020 Poseida Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate Cancer 05/20/2020 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Next page next › Last page last » Displaying 31 - 40 of 84
Poseida Therapeutics Reports Operational Update and Financial Results for Third Quarter 2020 11/12/2020
Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate Cancer 11/02/2020
Poseida Therapeutics and TScan Therapeutics Announce Research Collaboration and License Agreement to Explore Developing Allogeneic T Cell Receptor Therapies for the Treatment of COVID-19 10/21/2020
Poseida Therapeutics to Present CAR-T Manufacturing Process Optimization Data at CAR-TCR Digital Week 2020 09/16/2020
Poseida Therapeutics Reports Operational Update and Financial Results for Second Quarter and First Half of 2020 08/20/2020
Poseida Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate Cancer 05/20/2020